Advertisement


Kieron M. Dunleavy, MD, on B-Cell Malignancies: Novel-Novel Drug Combinations

Pan Pacific Lymphoma Conference 2018

Advertisement

Kieron M. Dunleavy, MD, of George Washington University, discusses the need for drug combinations to improve lymphoma therapy, despite unexpected toxicities, as our understanding of the molecular biology grows.



Related Videos

Lymphoma

Andrew D. Zelenetz, MD, PhD, on NHL: Clinical Applications of Genomic Studies

Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses the various ways genomics can be used in diagnosing and treating non-Hodgkin lymphoma and the need...

Lymphoma

Laurie H. Sehn, MD, MPH, on HGBCL With Comorbidities: Upfront Therapies

Laurie H. Sehn, MD, MPH, of the British Columbia Cancer Centre for Lymphoid Cancer, discusses the challenges of treating high-grade B-cell lymphoma in older patients and thos...

Sagar Lonial, MD, on Multiple Myeloma: Sequencing Therapies

Sagar Lonial, MD, of the Emory University School of Medicine, discusses the importance of planning for relapse based on the treatment a patient has received, new targets for refrac...

Lymphoma

Jonathan W. Friedberg, MD, on Follicular Lymphoma: Novel Combination Therapies

Jonathan W. Friedberg, MD, of the University of Rochester Medical Center, discusses treatments that enhance progression-free and overall survival and clear minimal residual disease...

Lymphoma

Steven M. Horwitz, MD, on CD 30+ PTCL Subtypes: Treatment Update

Steven M. Horwitz, MD, of Memorial Sloan Kettering Cancer Center, discusses aggressive subtypes of peripheral T-cell lymphoma and the coming data that may help clarify what c...

Advertisement

Advertisement



;
Advertisement